HB Fuller to acquire AMS for £715 million, expanding medical adhesives portfolio
Jun 25, 2026, 2:13 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Acquisition at a premium with strong synergy plan and deleveraging path; near-term stock reaction typically positive, contingent on regulatory clearance and AMS holder approval.
AI summary
What happened, with direct paths to the underlying reporting
HB Fuller has offered to acquire AMS for £715 million in cash, expanding its medical adhesives platform and driving higher-margin growth. The deal widens HB Fuller’s total addressable market to about $95 billion and targets roughly $55 million in run-rate synergies by 2031, financed 100% with a plan to de-leverage post-close. Approval from AMS shareholders and regulators is required, with close anticipated by year-end.
HB Fuller offers £715m cash for AMS; £2.85 per AMS share.
TAM expands to $95B; AMS adds surgical adhesives and biosurgicals.
Synergies run-rate ~£41m/$55m by 2031; includes cost reductions and sourcing
AMS provides pan-European footprint; accelerates HB Fuller’s US penetration.
Financing 100% committed; close targeted by year-end; AMS shareholder approval required.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
H.B. Fuller reports Q2 results after the close on June 24. Analysts expect EPS of $1.38 on about $923.6 million in revenue, and the company recently raised the dividend by 4.3%. A…
H.B. Fuller has made an unsolicited offer to acquire Advanced Medical Solutions, which may enhance Fuller’s healthcare product offerings following a failed previous buyout. This s…
J.P. Morgan maintains Underweight rating on FUL, lowering forecast to $50. First-quarter revenue fell 2.7% to $789 million, organic growth up 1.9%. Health segment saw EBITDA drop…
H.B. Fuller will release Q1 results on March 26. Analysts predict earnings of 50 cents per share, down from 67 cents last year. Revenue for the quarter is projected at $769.11 mil…